Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

boehringer ingelheim (malaysia) sdn. bhd. - metformin hydrochloride; linagliptin -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - metformin hydrochloride; linagliptin - tablet - 1000mg ; 2.5mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

boehringer ingelheim (malaysia) sdn. bhd. - linagliptin -

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - empagliflozin; linagliptin - tablet - 10mg; 5mg - empagliflozin 10mg; linagliptin 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - empagliflozin; linagliptin - tablet - 25mg; 5mg - empagliflozin 25mg; linagliptin 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - linagliptin 2.5mg;  ; metformin hydrochloride 1000mg - film coated tablet - 2.5 mg/1000 mg - active: linagliptin 2.5mg   metformin hydrochloride 1000mg excipient: arginine colloidal silicon dioxide copovidone hypromellose iron oxide red magnesium stearate maize starch propylene glycol purified talc purified water titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on metformin alone or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - linagliptin 2.5mg;  ; metformin hydrochloride 500mg - film coated tablet - 2.5 mg/500 mg - active: linagliptin 2.5mg   metformin hydrochloride 500mg excipient: arginine colloidal silicon dioxide copovidone hypromellose iron oxide yellow magnesium stearate maize starch propylene glycol purified talc purified water titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on metformin alone or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - linagliptin 2.5mg;  ; metformin hydrochloride 850mg - film coated tablet - 2.5 mg/850 mg - active: linagliptin 2.5mg   metformin hydrochloride 850mg excipient: arginine colloidal silicon dioxide copovidone hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch propylene glycol purified talc purified water titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on metformin alone or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Kenya - English - Pharmacy and Poisons Board

empagliflozin & linagliptin - tablet - empagliflozin 10 mg & linagliptin 5 mg /tablet - linagliptin and empagliflozin